- A. Health Biotechnology
- Areas of activity
- In vitro diagnostics
- Therapeutic areas
Founded in 2010, Amadix is a leading molecular diagnostics company focused on developing innovative diagnostic tests for early cancer detection to improve patient survival and quality of life.
The company's non-invasive assays tested in blood are oriented to early cancer detection avoiding the complications and side effects of existing invasive procedures and to improve the accuracy and compliance of currently marketed non-invasive tests.
ColoFast, the most advanced product developed so far, is an innovative blood-based test for colorectal cancer ) diagnosis based on a gene signature of micro-RNA (miRNA). The clinical validation of the test is currently undergoing a European prospective study and is planned to obtain CE-Mark in the coming months to be commercialized in 2019.
The company's test pipeline includes, in addition, two blood-based tests for early detection of lung and pancreatic cancer.